Vendor scorecard

Eden

48/100
Hold
United States · Telehealth (50 states) · US telehealth · hybrid brand + compounded GLP-1; vertically integrated via August 2025 acquisition of Contigo Compounding (now Eden Pharmacy, 503A); 127k+ members reported

Eden scored 48/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.

Not routable · on holdRead the rubricGet your match
11-signal breakdown
  • COA on every lot
    503A vertical integration via Eden Pharmacy improves direct-control on QC vs partner-pharmacy models, but 503A standards remain below 503B outsourcing-facility levels
    60
  • Cold-chain verified
    70
  • Rx legality
    Hybrid model · brand path is clean, compounded path under same April 30 503B-exclusion overhang as the rest of the cohort. 503A patient-specific compounding survives only with documented medical necessity post-Feb-2025
    45
  • Compound identity
    Vertical integration = direct compound-identity control; in-house pharmacy reduces partner-pharmacy variance
    60
  • Dose accuracy
    70
  • Endotoxin testing
    55
  • Refund posture
    60
  • Channel clarity
    Same-price-at-every-dose pricing transparent; hybrid brand + compounded means the routing question depends on which path the patient ends up on
    55
  • Support quality
    70
  • Price transparency
    Compounded $249/$349 (semaglutide/tirzepatide), brand $1,399-1,695. Same price across all doses is a real differentiator
    75
  • Longitudinal retention
    Vertical integration partially insulates against partner-pharmacy disruption (vs Mochi/Aequita pattern), but the broader 503B-exclusion final-rule still applies. Hold pending brand-pivot announcement or rule outcome
    50
Supply where Eden operates
Mounjaro
Stable

Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.

0d ago
Ozempic
Stable

Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.

1w ago
Rybelsus
Stable

Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.

1w ago
Wegovy
Stable

Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.

0d ago
Zepbound
Stable

Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.

0d ago
Full supply tracker across all regions →
Sources we audited against
How we score

The 11-signal rubric is public.

Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.

If Eden wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.

Full methodology →

Want a match for your situation?

Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.

Take the quiz

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.